oa SA Pharmaceutical Journal - Phosphodiesterase Type 5 inhibitors and erectile dysfunction : review
Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners', quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management of ED. The PDE5-inhibitors have provided an effective and patient acceptable therapy for ED. They have had a huge impact on public awareness and understanding of this disease. This article provides an overview of erectile dysfunction and the pharmacology, efficacy, safety and optimal use of the PDE5 inhibitors.
Article metrics loading...